ClinicalTrials.gg
CompletedNCT03480321Updated Jul 10, 2018

Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

A Phase 1 interventional study of Cilostazol 100 mg and PMR 150 mg in Intermittent Claudication, sponsored by Genovate Biotechnology Co., Ltd.,. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-10.

Sponsored by Genovate Biotechnology Co., Ltd., · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2018, 8 years 6 months ago, and no results have been posted to the registry.
Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The study is designed to evaluate the bioequivalency between the test formulations of extended-release tablet of cilostazol (PMR) administered once-daily and the reference formulation of immediate-release tablet of cilostazol (Cilostazol) administered twice-daily in normal healthy male and female subjects under fasting conditions.

02

Conditions studied

  • Intermittent Claudication

Keywords

  • Peripheral Artery Disease
  • Cilostazol
  • PMR
  • Extended-Release Tablet of Cilostazol
03

In context

Intermittent Claudication

309 studies on the registry are indexed under Intermittent Claudication; 46 are open to participants now.

This study's enrollment of 21 is below the median of 74 across 242 interventional studies indexed under Intermittent Claudication.

Browse Intermittent Claudication studies →

Lead sponsor

Genovate Biotechnology Co., Ltd., is the lead sponsor of 13 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be 18 to 45 years of age, inclusive.
  • Absence of diseases, such as heart failure, significant kidney impairment or a history of restricted blood flow to the heart, that could affect the study outcomes.
  • Having a (BMI) within normal standard limits (18.5\~24.9, inclusive).
  • Willing and able to give to participate in the clinical study and comply with all study procedures, restrictions and attend all visits.

Exclusion criteria

Exclusion Criteria:

  • History of bleeding tendency.
  • Use of anticoagulant agent(s) within 1 month prior to screening.
  • Use of tobacco or nicotine products within 6 months of screening.
  • Intake of over the counter or prescription drugs (other than hormonal ) within 2 weeks prior to randomization.
  • On any drug(s) or therapeutic device(s) within 30 days preceding screening; or anticipating use of any of these therapies during the course of the study (other than the study products).
  • History of substance abuse, such as alcohol, IV drugs, and inhaled drugs, within 1 year prior to screening.
  • Known history of having Acquired Immunodeficiency Syndrome (AIDS) or positive pre-study result of infection with (HIV); history or positive pre-study surface antigen or positive antibody result within 3 months of screening.
  • Pregnant or breast feeding.
  • Women of not using an effective birth control method. Women of child-bearing potential are defined as women physiologically capable of becoming pregnant, UNLESS they meet the following criteria:

    1. : 12 months of natural (spontaneous) amenorrhea or less than 12 months of spontaneous amenorrhea with serum Follicle Stimulating Hormone (FSH) levels > 40IU/L, OR;
    2. 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy, OR;
    3. Using one or more of the following acceptable methods of contraception: surgical sterilization (e.g. bilateral tubal ligation), hormonal contraception (e.g. implantable, injectable, vaginal patch, and oral), and double-barrier methods. Reliable contraception should be maintained throughout the study and for 7 days after study discontinuation.
  • Known or suspected to any ingredient of study drug(s).
  • Donated blood or lost more than 150 mL of blood within 3 months prior to randomization or plans to donate blood or plasma within 4 weeks after completion of the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Active comparator
    Cilostazol 100 mg

    Drug: Cilostazol 100 mg

  • Experimental
    PMR 150 mg

    Drug: PMR 150 mg

  • Experimental
    PMR 200 mg

    Drug: PMR 200 mg

Interventions

  • One immediately-release tablet (Cilostazol 100 mg) at 08:00 and another at 20:00, twice daily oral dose (total daily dose of 200 mg)

  • DrugPMR 150 mg

    Two extended-release tablets (PMR 150 mg) at 08:00, single oral dose (total daily dose of 300 mg)

  • DrugPMR 200 mg

    Two extended-release tablets (PMR 200 mg/tablet) at 08:00, single oral dose (total daily dose of 400 mg)

06

What researchers measure

Primary outcomes

  1. Area under the curve, from time zero to last measureable time point (AUC (0-t))

    Time frame: 0-72 hours after morning dose

  2. AUC from time zero to infinity (AUC (0-∞))

    Time frame: 0-72 hours after morning dose

07

Study locations

1 site
  • Bio-Kinetic Clinical Applications, LLC
    Springfield, Missouri 65802, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03480321
Lead sponsor
Genovate Biotechnology Co., Ltd.,
Responsible party
Sponsor
First posted
Mar 29, 2018
Start date
Mar 6, 2018
Primary completion
Apr 28, 2018
Completion
Jun 7, 2018
Last update
Jul 10, 2018

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion